AngII induces HepG2 cells to activate epithelial‑mesenchymal transition

Qi,Minghua; Zhou,Yuanping; Liu,Jikui; Ou,Xi; Li,Minghua; Long,Xia; Ye,Jing; Yu,Guangyin

doi:10.3892/etm.2018.6610

AngII induces HepG2 cells to activate epithelial‑mesenchymal transition

Authors:
- Minghua Qi
- Yuanping Zhou
- Jikui Liu
- Xi Ou
- Minghua Li
- Xia Long
- Jing Ye
- Guangyin Yu
View Affiliations

Affiliations: Department of Infectious Disease, Beijing University Shenzhen Hospital, Shenzhen, Guangdong 518035, P.R. China, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: August 16, 2018 https://doi.org/10.3892/etm.2018.6610
Pages: 3471-3477
Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine whether HepG2 can induce epithelial‑mesenchymal transition (EMT) via angiotensin II (AngII) simulation. The expression levels of EMT markers vimentin and E‑cadherin in cancer tissues and adjacent tissues of patients with hepatocellular carcinoma (HCC) were detected by immunohistochemistry. In addition, HepG2 cells were stimulated with AngII, and the gene and protein expression levels of vimentin and E‑cadherin were measured by reverse transcription‑quantitative polymerase chain reaction and western blot analyses, respectively, whereas cell migration and invasion were assessed using Transwell assays. The AngII inhibitor Ang1‑7 and the Ang1‑7 inhibitor A779 were added to the system to further evaluate AngII‑induced EMT. Compared with that in normal tissue, the expression level of vimentin in HCC tissue was increased, whereas that of E‑cadherin was decreased. EMT occurred 48 h following AngII stimulation. The transcription level of E‑cadherin in HepG2 cells was decreased, whereas that of vimentin was increased. In addition, the migration and invasion abilities of the cells were increased simultaneously. Ang1‑7 partly inhibited AngII‑induced EMT. When stimulated at an appropriate time, HepG2 cells have the ability to undergo EMT.

View Figures

View References

1	El-Serag HB and Rudolph L: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M, et al: Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Brit J Surg. 98:552–557. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 352:179–184. 1998. View Article : Google Scholar : PubMed/NCBI
4	Vinson GP, Barker S and Puddefoot JR: The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer. 19:R1–R19. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R and Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin. 135:1429–1435. 2009. View Article : Google Scholar
6	Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA and Torti FM: Phase I and pharmacokinetic study of angiotensin-(1–7), an endogenous antiangiogenic hormone. Clin Cancer Res. 15:7398–7404. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hallas J, Christensen R, Andersen M, Friis S and Bjerrum L: Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: A population-based case-control study. Brit J Clin Pharmaco. 74:180–188. 2012. View Article : Google Scholar
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
9	Liu Y, Li B, Wang X, Li G, Shang R, Yang J, Wang J, Zhang M, Chen Y, Zhang Y, et al: Angiotensin-(1–7) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin II type 1 receptor, angiotensin II type 2 receptor and mas receptor. Mol Med. 21:626–636. 2015. View Article : Google Scholar : PubMed/NCBI
10	Zhou L, Xue H, Wang Z, Ni J, Yao T, Huang Y, Yu C and Lu LM: Angiotensin-(1–7) attenuates high glucose-induced proximal tubular epithelial-to-mesenchymal transition via inhibiting ERK1/2 and p38 phosphorylation. Life Sci. 90:454–462. 2012. View Article : Google Scholar : PubMed/NCBI
11	Santhekadur PK, Akiel M, Emdad L, Gredler R, Srivastava J, Rajasekaran D, Robertson CL, Mukhopadhyay ND, Fisher PB and Sarkar D: Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGF-β signaling. FEBS Open Bio. 4:353–361. 2014. View Article : Google Scholar : PubMed/NCBI
12	Passos-Silva DG, Verano-Braga T and Santos RA: Angiotensin-(1–7): Beyond the cardio-renal actions. Clin Sci (Lond). 124:443–456. 2013. View Article : Google Scholar : PubMed/NCBI
13	Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA and Gallagher PE: Angiotensin-(1–7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 67:2809–2815. 2007. View Article : Google Scholar : PubMed/NCBI
14	Assimes TL, Elstein E, Langleben A and Suissa S: Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. 17:1039–1049. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M, et al: Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1/2, NF-kappa B and survivin. Int J Oncol. 34:1573–1582. 2009. View Article : Google Scholar : PubMed/NCBI
16	Attoub S, Gaben AM, Al-Salam S, Al Sultan MA, John A, Nicholls MG, Mester J and Petroianu G: Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci. 1138:65–72. 2008. View Article : Google Scholar : PubMed/NCBI
17	Wani S and Sharma P: The role of chemoprevention in Barrett esophagus and esophageal adenocarcinoma. J Clin Gastroenterol. 41 Suppl:S135–S140. 2007. View Article : Google Scholar
18	Arrieta O, Villarreal-Garza C, Vizcaino G, Pineda B, Hernandez-Pedro N, Guevara-Salazar P, Wegman-Ostrosky T, Villanueva-Rodriguez G and Gamboa-Dominguez A: Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumor Biol. 36:5627–5634. 2015. View Article : Google Scholar
19	George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer. 10:745–759. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
21	Zong H, Yin B, Zhou H, Cai D, Ma B and Xiang Y: Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. Tumor Biol. 36:5171–5177. 2015. View Article : Google Scholar
22	Qi MH, Ye J and Qi ZY: Angiotensin II induces hepatocellular carcinoma cell line SMMC-7721 to produce epithelial mesenchymal transition. Guangdong Med J. 36:1–3. 2015.(In Chinese).